111536
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
奥利西瑞林与丙泊酚复合用于无痛宫腔镜检查的有效剂量确定：一项前瞻性改良迪克森序贯剂量探索研究
Authors Yang K , Yuan Q, Huang H, Wang L, You J, Liu Q, Zhou Y, Luo Y, Liu Q
Received 20 August 2025
Accepted for publication 10 December 2025
Published 18 December 2025 Volume 2025:18 Pages 6903—6910
DOI https://doi.org/10.2147/JPR.S557764
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Timothy Atkinson
Ke Yang,1 Qian Yuan,1 Hao Huang,1 Lina Wang,1 Jingyu You,1 Qiaojie Liu,1 Yulin Zhou,2 Yi Luo,3 Qin Liu1
1Department of Anesthesiology, Zigong Maternal and Child Health Care Hospital, Zigong, People’s Republic of China; 2Department of Central Operating Room, Zigong Maternal and Child Health Care Hospital, Zigong, People’s Republic of China; 3Department of Gynecology, Zigong Maternal and Child Health Care Hospital, Zigong, People’s Republic of China
Correspondence: Qin Liu, Email 869422375@qq.com
Background: Oliceridine combined with propofol is suitable for intravenous anesthesia in painless hysteroscopy. This study aimed to determine the 50% effective dose (ED50) and 95% effective dose (ED95) of oliceridine compounded with propofol for painless hysteroscopy.
Methods: In all, 29 patients aged 18– 60 years who were scheduled for painless hysteroscopy under intravenous anesthesia were recruited, and a total of 26 patients were enrolled in the final analysis. The trial was conducted using the modified Dixon sequential method, with an initial dose of 1.5 mg of oliceridine, followed by 2.0– 2.5 mg/kg of propofol administered 1 minute later. Whether the dose of oliceridine was increased or decreased depends on the prior operation. If the hysteroscopy failed (positive response), which was defined as inadequate cervical dilatation, patient body movements, frowning, heart rate (HR), or mean arterial pressure (MAP) greater than 20% of the baseline value, or a MOAA/S score ≥ 2, the subsequent dosage of oliceridine was increased by 0.1 mg. Conversely, the dose was decreased by 0.1 mg. At least seven crossover waves had to occur before the formal test was stopped. The probit regression method was used to determine the ED50 and ED95 with 95% confidence intervals (CIs).
Results: The ED50 and ED95 of oliceridine in patients were 1.583 (95% CIs: 1.444– 1.857) mg and 1.848 (95% CIs: 1.701– 4.409) mg, respectively.
Conclusion: A dose of 1.848 mg oliceridine compounded with propofol provides an effective anesthesia approach for painless hysteroscopy. Future larger, multicenter studies will help to expand the population range of oliceridine use and explore its potential benefits and risks.
Keywords: ED50, ED95, oliceridine, painless hysteroscopy
1Department of Anesthesiology, Zigong Maternal and Child Health Care Hospital, Zigong, People’s Republic of China; 2Department of Central Operating Room, Zigong Maternal and Child Health Care Hospital, Zigong, People’s Republic of China; 3Department of Gynecology, Zigong Maternal and Child Health Care Hospital, Zigong, People’s Republic of China
Correspondence: Qin Liu, Email 869422375@qq.com
Background: Oliceridine combined with propofol is suitable for intravenous anesthesia in painless hysteroscopy. This study aimed to determine the 50% effective dose (ED50) and 95% effective dose (ED95) of oliceridine compounded with propofol for painless hysteroscopy.
Methods: In all, 29 patients aged 18– 60 years who were scheduled for painless hysteroscopy under intravenous anesthesia were recruited, and a total of 26 patients were enrolled in the final analysis. The trial was conducted using the modified Dixon sequential method, with an initial dose of 1.5 mg of oliceridine, followed by 2.0– 2.5 mg/kg of propofol administered 1 minute later. Whether the dose of oliceridine was increased or decreased depends on the prior operation. If the hysteroscopy failed (positive response), which was defined as inadequate cervical dilatation, patient body movements, frowning, heart rate (HR), or mean arterial pressure (MAP) greater than 20% of the baseline value, or a MOAA/S score ≥ 2, the subsequent dosage of oliceridine was increased by 0.1 mg. Conversely, the dose was decreased by 0.1 mg. At least seven crossover waves had to occur before the formal test was stopped. The probit regression method was used to determine the ED50 and ED95 with 95% confidence intervals (CIs).
Results: The ED50 and ED95 of oliceridine in patients were 1.583 (95% CIs: 1.444– 1.857) mg and 1.848 (95% CIs: 1.701– 4.409) mg, respectively.
Conclusion: A dose of 1.848 mg oliceridine compounded with propofol provides an effective anesthesia approach for painless hysteroscopy. Future larger, multicenter studies will help to expand the population range of oliceridine use and explore its potential benefits and risks.
Keywords: ED50, ED95, oliceridine, painless hysteroscopy